Biora Therapeutics, Inc. BIOR
We take great care to ensure that the data presented and summarized in this overview for BIORA THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BIOR
Top Purchases
Top Sells
About BIOR
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Insider Transactions at BIOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2024
|
Aditya P. Mohanty Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
819,000
+34.73%
|
-
|
|
Feb 15
2024
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
230,000
+31.85%
|
-
|
|
Feb 15
2024
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
325,000
+35.0%
|
-
|
|
Sep 18
2023
|
Athyrium Opportunities Iii Co Invest 1 LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
9,235,281
+45.8%
|
-
|
|
Aug 15
2023
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
210,175
+44.49%
|
-
|
|
Aug 15
2023
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
36,183
-41.02%
|
$108,549
$3.14 P/Share
|
|
Aug 15
2023
|
Aditya P. Mohanty Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
559,450
+43.71%
|
-
|
|
Aug 15
2023
|
Aditya P. Mohanty Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117,881
-42.26%
|
$353,643
$3.14 P/Share
|
|
Aug 15
2023
|
Eric D Esparbes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
219,650
+44.08%
|
-
|
|
Aug 15
2023
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,022
-40.41%
|
$120,066
$3.14 P/Share
|
|
Jun 14
2023
|
Jill Ann Howe |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+39.17%
|
-
|
|
Jun 14
2023
|
Jeffrey D. Alter |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+39.62%
|
-
|
|
Jun 14
2023
|
Lynne Powell |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+40.66%
|
-
|
|
Jun 14
2023
|
Brian L. Kotzin |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+40.66%
|
-
|
|
May 15
2023
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
2,368
-2.61%
|
$7,104
$3.35 P/Share
|
|
May 15
2023
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,807
-2.76%
|
$8,421
$3.35 P/Share
|
|
May 15
2023
|
Aditya P. Mohanty Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,249
-3.88%
|
$33,747
$3.35 P/Share
|
|
Mar 15
2023
|
Clarke Neumann |
SELL
Payment of exercise price or tax liability
|
Direct |
10,683
-10.55%
|
$21,366
$2.56 P/Share
|
|
Mar 15
2023
|
Clarke Neumann |
BUY
Grant, award, or other acquisition
|
Direct |
79,634
+29.89%
|
-
|
|
Mar 15
2023
|
Eric D Esparbes Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,216
-9.92%
|
$22,432
$2.56 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 11.6M shares |
|---|
| Payment of exercise price or tax liability | 194K shares |
|---|